Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 973,935
  • Shares Outstanding, K 68,878
  • Annual Sales, $ 76,010 K
  • Annual Income, $ -118,670 K
  • EBIT $ -138 M
  • EBITDA $ -128 M
  • 60-Month Beta 1.12
  • Price/Sales 12.31
  • Price/Cash Flow N/A
  • Price/Book 2.39

Options Overview Details

View History
  • Implied Volatility 87.58% ( -33.11%)
  • Historical Volatility 59.71%
  • IV Percentile 71%
  • IV Rank 39.08%
  • IV High 182.17% on 05/06/24
  • IV Low 26.89% on 09/11/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 23
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 3,595
  • Open Int (30-Day) 2,565

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.69
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.43 +13.76%
on 12/13/24
15.00 -5.73%
on 11/21/24
-0.41 (-2.82%)
since 11/20/24
3-Month
11.99 +17.93%
on 10/03/24
17.70 -20.11%
on 11/12/24
+1.05 (+8.02%)
since 09/20/24
52-Week
7.97 +77.42%
on 04/26/24
17.70 -20.11%
on 11/12/24
+4.87 (+52.54%)
since 12/20/23

Most Recent Stories

More News
Zymeworks Advances Solid Tumor Strategy with Five IND Applications Nomination and Expansion into Autoimmune Diseases

Zymeworks advances solid tumor and autoimmune disease therapies, including five IND applications ahead of schedule and innovative drug candidates.Quiver AI SummaryZymeworks Inc. has made significant progress...

ZYME : 14.14 (+4.12%)
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

ZYME : 14.14 (+4.12%)
Zymeworks Inc. Management to Participate in Multiple Upcoming Investor Conferences and R&D Day

Zymeworks Inc. announces management participation in several upcoming investor conferences and a Research & Development Day.Quiver AI SummaryZymeworks Inc., a clinical-stage biotechnology company focused...

ZYME : 14.14 (+4.12%)
Zymeworks Inc. Announces FDA Accelerated Approval of Ziihera® for HER2-Positive Biliary Tract Cancer, the First Dual HER2-Targeted Bispecific Antibody Approved in the U.S.

Ziihera is the first FDA-approved bispecific antibody for HER2-positive biliary tract cancer, achieving a 52% response rate.Quiver AI SummaryZymeworks Inc. announced that the U.S. FDA has granted accelerated...

ZYME : 14.14 (+4.12%)
Zymeworks Announces Participation in Upcoming Investor Conferences

ZYME : 14.14 (+4.12%)
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

ZYME : 14.14 (+4.12%)
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

ZYME : 14.14 (+4.12%)
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

ZYME : 14.14 (+4.12%)
Zymeworks Announces Participation in Upcoming Investor Conferences

ZYME : 14.14 (+4.12%)
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

ZYME : 14.14 (+4.12%)

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 15.53
2nd Resistance Point 14.84
1st Resistance Point 14.49
Last Price 14.14
1st Support Level 13.45
2nd Support Level 12.76
3rd Support Level 12.41

See More

52-Week High 17.70
Last Price 14.14
Fibonacci 61.8% 13.98
Fibonacci 50% 12.84
Fibonacci 38.2% 11.69
52-Week Low 7.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar